Sravnitel'naya kliniko-diagnosticheskaya znachimost' nekotorykh serologicheskikh opukholeassotsiirovannykh markerov dlya razlichnykh gistologicheskikh tipov raka legkogo

Abstract

The authors selected a combination of serological tumor-associated markers for each histological type of tumors to enhance the sensitivity of clarifying laboratory diagnosis and monitoring of patients with lung cancer (LC). The serum levels of carcinogenic embryonic antigen (CEA), SCC, Cyfra 21-1, and ProGRP were studied in 57 primary patients with Stages I-IV LC of various histological types (squamous-cell and small-cell carcinoma, adenocarcinoma), in 12 patients with noncancer lung diseases, and in 13 healthy individuals. The highest sensitivity was demonstrated by the combined determination of Cyfra 21-1 and SCC for squamous-cell LC (88.2%) and that of CEA and Cyfra 21-1 for lung adenocarcinoma (57.1%). On a small sample of patients, the new serological marker ProGRP showed not only a high sensitivity (75%) for small-cell LC, but also a high specificity (94.3%) for non-small-cell LC. These results agree with few data in the foreign literature and suggest that the marker should be used for the specifying differential diagnosis of small-cell LC and the monitoring of patients with type of LC.

Keywords

ProGRP / SCC / Cyfra 21-1 / lung cancer / tumor-associated marker / ProGRP / SCC / carcinogenic embryonic antigen / Cyfra 21-1

References

[1] European Group on Tumor Markers: Consensus recommendations // Anticancer Res. - 1999. - Vol. 19, N 4A. - P. 2789- 2819.

[2] Faten-Moghadam A., Stieber P. Sensible Use of Tumor Markers / Ed. J. Hartmann. - Basel, 1993.

[3] Oremek G. M., Seiffert U. B., Siekmeier R. et al. // Med. Klin. - 1995. - Bd 90, N 1. - S. 23-26.

[4] Practice Guidelines and Recommendations for Use of Tumor Markers in the Clinic // Nat. Acad. Clin. Biochem. - 2002. - Vol. 15. - P. 1-56.

[5] Schneider J. // Clin. Lab. - 2003. - Vol. 49. - P. 35-42.

RIGHTS & PERMISSIONS

Eco-Vector